24/7 Wall St. looks at some big analyst calls that we have seen so far on Tuesday, including Apple, Array Technologies, CareDx and Vertex Pharmaceuticals.
Here are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. They are not penny stocks with absolutely no track record or...
Tuesday's top analyst upgrades and downgrades included Beyond Meat, Dun & Bradstreet, Evoqua Water Technologies, Microchip Technology, Skyworks Solutions, SunPower and Texas Instruments.
Companies winning approval from the FDA or beating a trial are expected in some cases. If investors already have priced this news into the stock, when it actually comes around they tend to sell the...
Wednesday's top analyst upgrades, downgrades and initiations included Akamai Technologies, Alibaba, Boeing, Goodyear Tire & Rubber, Lyft, Micron Technology, Nvidia, T-Mobile, Under Armour, Wynn...
Ardelyx shares dropped on Friday after the firm announced that the FDA has approved its treatment of irritable bowel syndrome with constipation in adults.
Ardelyx shares jumped on Tuesday after the firm announced positive results from its late-stage study in dialysis patients who have uncontrolled hyperphosphatemia.
Here are five biotech stocks that are rated Buy by the Jefferies analysts, are trading under the $10 level and could provide investors with some solid upside potential.
After screening the daily 24/7 Wall St. analyst research database, we found five stocks trading under $10 that analysts feel could bring investors solid upside potential.
The top analyst upgrades, downgrades and other research calls from Thursday include Ardelyx, Juniper, Kroger, Phillips 66, Square, Transocean and Walmart.
Wedbush has issued a report with some of its best ideas for 2016. These top six ideas from this list have implied upside of at least 50%.
These three biotech companies not only have data that could prove to be huge, but they have been absolutely hammered over the last year and are offering aggressive accounts the best entry points in...
Ardelyx recently filed with the U.S. Securities and Exchange Commission (SEC) regarding a secondary offering.
Biotech gets a lot of sustained attention, but some stocks still fall through the cracks, either due to recent failures or general lack of interest.
With Chinese stocks crashing another 6% and oil pushing $40 a barrel, sometimes we need to be reminded that good things still happen in the corporate world. And indeed they do, as the past few days...